Clinical Scorecard: Elevated Plasma F2-Isoprostanes Correlate with Higher Fracture Risk in Individuals with Type 2 Diabetes
At a Glance
Category
Detail
Condition
Type 2 Diabetes-associated bone fragility and fracture risk
Key Mechanisms
Increased oxidative stress measured by plasma F2-isoprostanes correlates with higher fracture risk independent of bone mineral density
Target Population
Older adults aged 70-79 years with type 2 diabetes
Care Setting
Ambulatory clinical settings managing older adults with type 2 diabetes
Key Highlights
Each standard deviation increase in log plasma F2-isoprostanes is associated with a 93% increase in incident clinical fracture risk in type 2 diabetes.
No significant association between plasma F2-isoprostanes and fracture risk was observed in non-diabetic individuals.
Plasma F2-isoprostanes negatively correlate with baseline and 4-year total hip bone mineral density in type 2 diabetes.
Guideline-Based Recommendations
Diagnosis
Consider measuring plasma F2-isoprostanes as a marker of oxidative stress to assess fracture risk in older adults with type 2 diabetes.
Management
Incorporate oxidative stress evaluation alongside bone mineral density to better estimate fracture risk in type 2 diabetes.
Address oxidative stress as a potential therapeutic target to reduce bone fragility in type 2 diabetes.
Monitoring & Follow-up
Monitor plasma F2-isoprostanes levels longitudinally to evaluate fracture risk progression in type 2 diabetes patients.
Risks
Standard fracture risk tools like FRAX may underestimate fracture risk in type 2 diabetes; oxidative stress markers provide additional risk stratification.
Patient & Prescribing Data
Older adults with type 2 diabetes aged 70-79 years
Elevated oxidative stress indicated by plasma F2-isoprostanes is linked to increased fracture risk independent of bone mineral density, suggesting the need for adjunctive therapeutic strategies beyond BMD-focused treatments.
Clinical Best Practices
Use plasma F2-isoprostanes measurement to improve fracture risk assessment in type 2 diabetes patients.
Recognize oxidative stress as a modifiable factor contributing to bone fragility in type 2 diabetes.
Combine BMD testing with oxidative stress markers to guide preventive and treatment strategies for fractures in type 2 diabetes.
Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.
Regeneron Genetics Center’s Luca Lotta explains how population-scale genetic evidence can reveal more promising drug targets and open new possibilities for disease prevention
